Breast cancer survival studies in India: a review

Jignasa Sathwara¹*, Saurabh Bobdey¹, Ganesh B.²

¹PhD student, Department of Medical Records, Biostatistics and Epidemiology, Tata Memorial Hospital, Mumbai, India
²HOD, Department of Medical Records, Biostatistics and Epidemiology, Tata Memorial Hospital, Mumbai, India

Received: 11 June 2016
Accepted: 01 July 2016

*Correspondence:
Jignasa Sathwara,
E-mail: jignasa.sathwara@gmail.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Length of survival of cancer patients is an important indicator for knowing the outcome of treatment in any study. Epidemiological features and biological profile of breast cancer appear to be different in developing countries as compared to Western countries. Knowing the factors that influence survival rates among women with breast cancer may help define early detection actions, and improve treatment and care proposals in all the areas of health. Therefore, this study aims to identify, the publications defining the factors influencing survival for women with breast cancer in India. PUBMED database was searched from January 1990 to April 2016, using the key words Breast cancer, breast cancer outcome and Survival and their corresponding Mesh terms were used in combination with Boolean operators like OR, AND. Five year overall survival rate of breast cancer in India ranged from 40-62%. The results from 16 publications showed that survival of breast cancer varies widely depending on number of factors like age, stage at diagnosis, marital status, educational level, hormonal status, clinical extent of disease and treatment. The publications that make up this review present contributing factors that affect the survival rate of women with breast cancer in India. This information on survival studies can pinpoint the lacunae in treatment modalities and can guide us to do basic and translational research so the preventive strategies can be implemented.

Keywords: Survival rate, Breast cancer, India

INTRODUCTION

Breast cancer is one of the most commonly diagnosed malignancies and the leading cause of cancer death in women over the world.¹² A variety of risk factors for breast cancer have been well-established by epidemiologic studies. These include non-modifiable factors such as age, family history of cancer, benign breast disease, breast density and genetics, as well as modifiable exposures related to diet, physical inactivity, exogenous hormones and certain female reproductive factors.³⁴ Breast cancer is considered as a heterogeneous condition and so requires evaluation of as many clinical and pathological features as possible to allow for best prediction of survival.⁷ Survival refers to the occurrence of a specific event of interest, starting from an initial time until a final time, for example, from the diagnosis of breast cancer to the death.⁸ The study of cause and effect relationships is a basis of research and measurement of survival time is necessary for evaluation of chronic diseases.⁹ Length of survival of cancer patients is an important indicator for knowing the outcome of treatment in any study.⁹

Disease free survival and Overall survival are commonly used in breast cancer prognosis. A recent Lancet publication with global data showed age standardized net survival with breast cancer of 80% or more in 34 countries and an increase worldwide but had no data on factors influencing it.¹⁰ Knowing the factors that influence survival rates among women with breast cancer may help define early detection actions, and improve treatment and care proposals in all the areas of health. Therefore, this study aims to identify, the publications.
defining the factors influencing survival for women with breast cancer in India.

**Data sources and searches**

The research question that gave rise to the study was: which factors influence survival among women with breast cancer studies in India? This paper is based on information gathered from a review of peer-reviewed publications on breast cancer survival studies in India. MEDLINE (http://www.pubmed.com) was searched from January 1990 to April 2016, using the keywords such as “breast cancer, survival rate, survival analysis, and their corresponding mesh terms were also used in combination with Boolean operators OR, AND.” We also examined bibliographies of included articles to identify additional references. The search strategy was limited to English language. Only journal article type was included.

**Study selection**

**Inclusion criteria**

- Study designs eligible for inclusion in our review were randomized controlled trials, nonrandomized controlled trials and cohort studies conducted to evaluate the survival rate of women with breast cancer at five years or the disease-free survival rate at five years.
- Studies conducted in India only were included in the review.

**Exclusion criteria**

Studies not providing data on survival were evaluated and excluded from the review.

**Data extraction and analysis**

The title and abstract of each citation were screened first, and full report was screened second if necessary to select the relevant articles according to selection criteria. Full texts of these selected studies were retrieved and reviewed. A total of 16 studies were included in the review, and their findings have been presented. We extracted the following information from the full texts: First Author, the study design, study site, number of subjects, 5 year overall survival (OS) rate, relative survival (RS) and disease-free survival (DFS) and factors that affect survival rates. The data were entered into Microsoft Excel spreadsheets (Table 1).

**DISCUSSION**

Many factors influence the survival of patients with breast cancer; they include patient factors, stage of disease, tumour biology, and cancer treatment. Population-based studies on breast cancer in India have showed five-year survival rates ranged from 42-48%, whereas hospital based studies across India shows 5 year relative survival rate ranged from 40-45%.\(^{11-15}\) Five-year survival rates of more than 80% have been reported in many studies from the West and also from a developed Asian country in India.\(^{16,17}\) The poor overall survival rate of breast cancer reflects delay in diagnosis, advanced stages of disease at presentation, and, probably, inadequate facilities for early diagnosis and treatment.\(^ {18}\)

**Age at diagnosis**

Age is known to be an important factor that determines the prognosis. The epidemiological data encountered that the younger patients (<35 years) had better survival than older patients.\(^ {19-23}\) whereas in some studies younger age has been generally accepted as an independent adverse prognostic indicator of survival in breast cancer.\(^ {24,27}\) A review of the US National Cancer Database revealed that patients younger than 35 years had more advanced disease at diagnosis and a poorer 5-year survival rate than older premenopausal patients.\(^ {28}\) Similar findings have been reported in the past.\(^ {29,30}\)

**Education status**

Relating the survival rate to education, studies have shown that women with higher education had better overall five-year survival rates as compared to illiterate.\(^ {20,21}\) Educational level can be taken as an indirect indicator of social class. Socio-economic status is an important factor in the survival of women with breast cancer.\(^ {31}\) In several populations, it has been reported that women in higher social classes have higher survival rates than those in lower social classes.\(^ {32}\) The lack of access to healthcare services may explain the direct relationship between the late stage diagnosis and educational levels.\(^ {33}\)

**Religion**

India is a vast country with wide varying social, cultural and religious practices. Cultural dynamics and sociodemographic differences cross population subgroups modulate how biologic disease is expressed among different ethnic groups.\(^ {16}\) These interactions contribute to the observed variations in breast carcinoma incidence, mortality and survival. Yeole et al showed muslims had a better and christians a lower survival as compared to Hindus. The factors like life style of patient, level of exercise, early marriage, and other reproductive factors plays an important role in the survival rate of breast cancer patients.\(^ {34}\)

**Marital status**

Indian women would not readily discuss issues concerning the breast with others. This is more pronounced in single women who may not have intimate partners and are less likely to discuss their breast symptoms with someone else immediately. This phenomenon is recognized as a contributory factor to delay in seeking help.\(^ {31}\) Gajlakshmi et al showed single
Stage of disease

Stage of disease at diagnosis is a critical determinant in breast cancer survival. On average, 50% of breast cancer cases in India present at late stage (stage III and IV). Whereas in developed countries like the United States, only 12% of the breast cancer cases are diagnosed at an advanced stage. Most of the Indian studies have shown an inverse relationship of stage-of-disease with survival. Late presentation is associated with advanced stages of tumor before treatment and poor survival.

Table 1: Description of included studies qualitative synthesis.

<table>
<thead>
<tr>
<th>Author</th>
<th>Type of study</th>
<th>Study site</th>
<th>No. of patients studied</th>
<th>5 year survival rate</th>
<th>Factors influencing survival</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nair et al&lt;sup&gt;18&lt;/sup&gt;</td>
<td>Retrospective-Hospital based</td>
<td>Kerala</td>
<td>449</td>
<td>OS 40%</td>
<td>Age, response to treatment, stage and regional nodal involvement</td>
</tr>
<tr>
<td>Nandakumar et al&lt;sup&gt;21&lt;/sup&gt;</td>
<td>Retrospective-PBCR</td>
<td>Bangalore</td>
<td>1381</td>
<td>OS 42.3% and RS 46.8%</td>
<td>Clinical extent of disease and educational status</td>
</tr>
<tr>
<td>Gajalakshmi et al&lt;sup&gt;23&lt;/sup&gt;</td>
<td>PBCR</td>
<td>Madras</td>
<td>1747</td>
<td>OS 48% and RS 51%</td>
<td>Age, Marital status, education status and clinical extent of disease</td>
</tr>
<tr>
<td>Gajalakshmi et al&lt;sup&gt;24&lt;/sup&gt;</td>
<td>Retrospective-Hospital based</td>
<td>Chennai</td>
<td>67</td>
<td>RS for CBC 47%</td>
<td>Age at diagnosis, family history of cancer and stage</td>
</tr>
<tr>
<td>Yeole et al&lt;sup&gt;25&lt;/sup&gt;</td>
<td>PBCR</td>
<td>Mumbai</td>
<td>2516</td>
<td>RS 46.2%</td>
<td>Age, Marital status, Religion, Education status, and clinical extent of disease</td>
</tr>
<tr>
<td>Dinshaw et al&lt;sup&gt;26&lt;/sup&gt;</td>
<td>Retrospective-single institution</td>
<td>Mumbai</td>
<td>1022 EBC</td>
<td>OS 87% and DFS 76%</td>
<td>Lymphovascular emboli or invasion (LVI), nodal status and systemic adjuvant treatment.</td>
</tr>
<tr>
<td>Raina et al&lt;sup&gt;50&lt;/sup&gt;</td>
<td>Retrospective-single institution</td>
<td>New Delhi</td>
<td>487 EBC</td>
<td>OS 73% and DFS 78%</td>
<td>Age, tumor size, nodal status, stage and number of positive lymph nodes</td>
</tr>
<tr>
<td>Deo SV et al&lt;sup&gt;51&lt;/sup&gt;</td>
<td>Retrospective-single institution</td>
<td>New Delhi</td>
<td>902</td>
<td>DFS 82% and OS 88%</td>
<td>Tumor size, nodal involvement, ER/PR status, and Breast conservation therapy</td>
</tr>
<tr>
<td>Yadav BS et al&lt;sup&gt;52&lt;/sup&gt;</td>
<td>Retrospective-single institution</td>
<td>Chandigarh</td>
<td>688</td>
<td>DFS 69% and OS 81 %</td>
<td>PMRT, menopausal status, tumor stage and pathological nodal status.</td>
</tr>
<tr>
<td>Yadav et al&lt;sup&gt;53&lt;/sup&gt;</td>
<td>Retrospective-single institution</td>
<td>Chandigarh</td>
<td>141</td>
<td>LRR 6% and RFS 94%.</td>
<td>Tumor stage and pathological nodal stage, response to chemotherapy, type of surgery, extracapsular extension (ECE) and tamoxifen therapy.</td>
</tr>
<tr>
<td>Ganesh B et al&lt;sup&gt;54&lt;/sup&gt;</td>
<td>Retrospective-Hospital based</td>
<td>Mumbai</td>
<td>471</td>
<td>OS 67%</td>
<td>Age, Educational status and stage at diagnosis, treatment(Surgery)</td>
</tr>
<tr>
<td>Shanta et al&lt;sup&gt;55&lt;/sup&gt;</td>
<td>Retrospective-hospital based</td>
<td>Chennai</td>
<td>1,117</td>
<td>DFS 75%</td>
<td>Nodal staging, nodal status and tumor sterility.</td>
</tr>
<tr>
<td>Raina V et al&lt;sup&gt;57&lt;/sup&gt;</td>
<td>Retrospective-single institution</td>
<td>New Delhi</td>
<td>609 LABC patients</td>
<td>OS 58% and DFS 41%</td>
<td>Clinical response to chemotherapy</td>
</tr>
<tr>
<td>Haroon Ali et al&lt;sup&gt;58&lt;/sup&gt;</td>
<td>Retrospective-Hospital based</td>
<td>Meerut city</td>
<td>285</td>
<td>OS 51%</td>
<td>Age, Religion, educational, laterality tumor size, treatment factors</td>
</tr>
<tr>
<td>Khadakban et al&lt;sup&gt;59&lt;/sup&gt;</td>
<td>Retrospective review - Prospective database</td>
<td>Kerala</td>
<td>196 cases of MBC</td>
<td>Median OS 26.63 months (95% CI – 16.69–36.57)</td>
<td>Age, ER/PR status, Her-2 neu status, site of metastases and level of metastatic suspicion.</td>
</tr>
<tr>
<td>Vettuparambil et al&lt;sup&gt;60&lt;/sup&gt;</td>
<td>Retrospective-cohort study</td>
<td>Kerala</td>
<td>189</td>
<td>OS 71.4%</td>
<td>Stage of the disease, axillary nodal status, and hormone-receptor status</td>
</tr>
</tbody>
</table>

prognosis. This condition is now a leading cause of cancer deaths among Indian women.\textsuperscript{36} The women present late because of the lack of knowledge and awareness.

**Clinical factors**

Tumour biology is likely the most important; secondly, the treatment options and the response to the treatment (Figure 2). Breast cancer survival is driven by the variability of the patients and their tumours.\textsuperscript{37}

Axillary nodal status, age, tumour size, pathologic grade, and hormone receptor status are the established prognostic and/or predictive factors for selection of adjuvant treatments.

**Table 2: Factors influencing breast cancer survival.**

<table>
<thead>
<tr>
<th>Patient Characteristics</th>
<th>Treatment</th>
<th>Histopathological Features</th>
<th>Receptor status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at Diagnosis</td>
<td>Surgery</td>
<td>Histologic subtype</td>
<td>Estrogen receptor</td>
</tr>
<tr>
<td>Education</td>
<td>Radiation</td>
<td>Axillary lymph node metastasis</td>
<td>Progesterone receptor</td>
</tr>
<tr>
<td>Marital status</td>
<td>Chemotherapy</td>
<td>Tumour size</td>
<td>Her2 neu receptor</td>
</tr>
<tr>
<td>Religion</td>
<td></td>
<td>Histological Grade</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lymphovascular invasion</td>
<td></td>
</tr>
</tbody>
</table>

Breast cancer is commonly treated by various combinations of surgery, chemotherapy, radiation therapy, hormone therapy and targeted therapy via a multimodality approach. Selection of therapy is influenced by clinical and pathologic features that could predict their response to these therapies (Table 2). In the developed countries, breast cancer is treated using evidence-based recommendatory treatment schemes.\textsuperscript{37} Treatment plan is individually devised for each patient with respect to the clinical manifestations, the extent of the process, and the morphology of the tumor. Hormone receptor status is an important prognostic and therapeutic tool in breast cancer.\textsuperscript{43-46}

**CONCLUSION**

The publications that make up this review present contributing factors that affect the survival rate of women with breast cancer in India. This information on survival provides clinicians and researchers with opportunities to explore breast cancer trends, to measure progress against breast cancer, and to examine implications for breast cancer control in the context of associations with risk factors, prevention interventions, and the dissemination of advances in treatment. The survival studies can pinpoint the lacunae in treatment modalities and can guide us to do basic and translational research so the preventive strategies can be implemented.

**Funding:** No funding sources  
**Conflict of interest:** None declared  
**Ethical approval:** Not required

**REFERENCES**


